Aptevo Therapeutics Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 2401 4TH AVE., SEATTLE, WA, 98121
Mailing Address 2401 4TH AVE., SEATTLE, WA, 98121
Phone 206-838-0500
Fiscal Year End 1231
EIN 811567056
Financial Overview
FY2024
$12.22M
Stockholders' Equity
$16.90M
Cash & Equivalents
$-87.38
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | February 3, 2026 | View on SEC |
| 424B4 Prospectus for IPO or offering | January 30, 2026 | View on SEC |
| S-1 IPO registration statement | January 28, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | January 26, 2026 | View on SEC |
| 8-K Current report of material events | January 9, 2026 | View on SEC |
| 8-K Current report of material events | December 29, 2025 | View on SEC |
| 8-K Current report of material events | December 9, 2025 | View on SEC |
| 424B4 Prospectus for IPO or offering | November 25, 2025 | View on SEC |
| 4 Insider stock transaction report | November 12, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 7, 2025 | View on SEC |
Material Events
8-K Leadership Change February 3, 2026
High Impact
- Planned and orderly leadership transition ensures continuity with former CEO Marvin L. White transitioning to Executive Chair.
- Internal promotion of Jeff Lamothe (COO, former CFO) to President and CEO brings strong financial and operational expertise.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.